DSIP (Delta Sleep-Inducing Peptide): A Nonapeptide of the Stress and Sleep Axis

Research summary. Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide first isolated in the 1970s by the laboratory of Marcel Monnier and Guido Schoenenberger at the University of Basel, who observed that cerebral venous blood from sleeping rabbits contained a factor capable of inducing slow-wave (delta) sleep when transferred to recipient animals. The molecule has been studied across sleep research, stress adaptation, analgesia, and neuroprotection, but its endogenous receptor — if a single one exists — has never been definitively identified, which has shaped both its scientific reputation and the pace of translational interest.

Molecular profile

• Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE)
• Molecular formula: C₃₅H₄₈N₁₀O₁₅
• Molecular weight: ~848.8 g/mol
• CAS Number: 62568-57-4
• Synonyms: Emideltide, Deltaran (the latter being a Russian-developed formulation)

DSIP is unusual among bioactive peptides in that it appears to be relatively widely distributed across peripheral and central tissues at concentrations of comparable order of magnitude — suggesting a systemic regulatory role rather than a localised neuropeptide signalling function.

Mechanism of action

The mechanistic picture for DSIP remains genuinely uncertain. No high-affinity receptor has been definitively identified despite decades of investigation. Reported activities are likely a sum of several phenomena:

• Modulation of stress-axis signalling. DSIP has been associated with effects on corticotropin secretion and hypothalamic–pituitary–adrenal axis tone in rodent models.
• Antioxidant and free-radical scavenging activity. A recurrent finding in the rodent literature is that DSIP attenuates lipid peroxidation and reactive oxygen species in tissues exposed to ischaemic, hypoxic, or chemical stress.
• Modulation of sleep architecture. Effects on sleep have been variable across studies and species, with reports including increased slow-wave sleep, paradoxical sleep effects, transient arousal followed by sedation, and subjective improvements in chronic poor sleepers — but with often poor correspondence between subjective and EEG-measured outcomes.
• Possible interaction with central opioid systems. Some analgesic effects have been ascribed to opioid pathway engagement, though without evidence of dependency or tolerance in the available preclinical work.

Preclinical and clinical research highlights

Sleep research. The original discovery context. Subsequent work has produced a mixed picture: while some studies in animals and humans have reported promotion of slow-wave sleep, others have reported transient activation followed by improved sleep continuity, and still others have failed to replicate the effects observed in the founding experiments. The original observations stand, but the magnitude and reliability of DSIP's sleep-modulating effects have been the subject of ongoing debate.

Analgesia and addiction-related research. Russian and Eastern European groups have reported reductions in chronic pain perception and substantial relief of withdrawal symptoms in alcohol and opioid detoxification studies. The clinical methodology in these reports does not always meet contemporary trial-design standards, but the body of work is extensive enough to support continued mechanistic interest.

Stress and metabolic resilience. Animal studies have reported preservation of oxidative phosphorylation and mitochondrial function under hypoxic and ischaemic conditions, with reductions in markers of metabolic injury in stroke and myocardial-ischaemia models.

Antioxidant and anti-tumour effects. Long-term DSIP administration in rodents has been associated with reductions in spontaneous tumour incidence and reduced chromosomal abnormalities in some studies. These observations have been incorporated into the broader Russian gerontological literature alongside other peptide bioregulators.

Depression-related studies. Reduced DSIP levels have been reported in patients with major depressive disorder in some clinical investigations, alongside disturbances in sleep architecture and HPA-axis function — observations that have prompted continued interest in the peptide's role at the intersection of sleep and mood regulation.

A note on the evidence base

DSIP occupies an unusual place in the peptide research literature. It has been studied for almost five decades, has accumulated a sizeable preclinical and clinical record, and remains commercially available as a research peptide and (in some jurisdictions) as a regulated formulation. At the same time, the absence of a defined receptor mechanism, the variability of reported sleep effects, and the heavy concentration of the more positive clinical literature in non-Western journals have prevented it from reaching the threshold of mainstream therapeutic acceptance. Researchers approaching DSIP should be familiar with both the historical breadth of the literature and the methodological caveats associated with much of it.

Current research status

DSIP remains an investigational research peptide in Western research contexts. It is not approved as a therapeutic by the U.S. FDA or EMA. In Russia, formulations such as Deltaran have been used in clinical contexts. Within research, the molecule serves as:

• A historical reference compound in sleep neuroscience
• A research tool for stress-axis and oxidative-stress models
• A subject of ongoing mechanistic investigation aimed at identifying its receptor target

Key takeaways for researchers

• DSIP is a naturally occurring nonapeptide originally isolated from the cerebral venous blood of sleeping rabbits.
• Despite decades of study, no defined high-affinity receptor has been identified.
• Reported effects span sleep architecture, stress adaptation, analgesia, antioxidant activity, and possible anti-tumour activity in long-term rodent studies.
• The literature is mixed in quality and origin; the molecule is not an approved therapeutic in the U.S. or EU.

References

1. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences USA. 1977;74(3):1282–1286.

---

This article is provided for educational and research purposes only. DSIP is a research peptide. It is not an approved drug or therapeutic agent (in the U.S. or EU) and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.